• E-mail page
• Print page
• Text size   

Supporting your at-risk patients with their treatment plan is another way AstraZeneca can help you redefine success. This section contains educational materials, support programs, and money-saving offers to help your patients understand the importance of managing cholesterol and slowing the progression of atherosclerosis.

Order Patient Education Materials Now

AZOnDemand™ is your online source for free, easy-to-order patient education materials. Give your patients the information they need to understand cholesterol and live a healthier lifestyle.

> Find patient education materials

Interactive Tools

Access a suite of tools, including a Meal Planner and a Diet and Exercise Diary, to help engage at-risk patients. You can also e-mail these tools directly to your patients.

> Access interactive tools

Patient Support Programs

AstraZeneca has created several programs to help your at-risk patients understand the importance of managing cholesterol and slowing the progression of atherosclerosis. Find out more about the CRESTOR 360°™ Patient Support Program, the Take Action Kit, and the AZ&Me™ Prescription Savings Program.

> See patient support programs

Money-Saving Offers

AstraZeneca understands that, at times, the help patients need most is financial. We have created several programs and rebates to help ease the financial burden of taking prescription medications.

> Find money-saving offers

Consumer Awareness Campaign

A patient who understands his or her condition is more likely to follow therapy. AstraZeneca is committed to helping improve the dialogue between patients and doctors. See how our consumer communications and online tools can help.

> Review the campaign

• CRESTOR is indicated^# as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia and to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. CRESTOR is not indicated to reduce cardiovascular morbidity and mortality

Important safety information about CRESTOR

• CRESTOR is contraindicated^# in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers
• Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level but are increased at the highest dose (40 mg)
• CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir
• Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever
• CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose
• It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (eg, semiannually) thereafter. Should an increase in ALT or AST of >3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume substantial quantities of alcohol
• In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%)^‡‡